IXICO plc
London Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bram Goorden
- Full Time Employees
- 81
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Griffin Court London United Kingdom EC1A 9PN
- IPO Date
- Apr 25, 1996
- Website
- ixico.com
- Similar Companies
- Business
- IXICO plc is a United Kingdom-based company specializing in neuroscience imaging and biomarker analytics, primarily serving the global biopharmaceutical industry. It provides technology-enabled specialty services including advanced imaging biomarker analysis; clinical trial management and operations; AI-driven data analytics platforms; drug development analytics; consultancy services; and post-marketing surveillance. IXICO’s services focus on neurological diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and other rare neurodegenerative disorders. Their proprietary AI-driven platform enables precise imaging and biomarker measurement, supporting decision-making in drug safety, efficacy, patient eligibility, and disease progression during clinical trials. IXICO operates internationally, with significant presence in the UK, Europe, and expanding commercial activities notably in the United States. Founded in 2004 and headquartered in London, the company has built a 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) in neuroscience clinical research. In the last 1-2 years, IXICO has undertaken major strategic initiatives including the appointment of Bram Goorden as CEO in 2024, who updated the company’s growth strategy focused on innovation, leadership, and scaling operations. The company completed a £4 million oversubscribed capital raise in October 2024 to fund expansion, particularly targeting growth in Alzheimer's and Parkinson's clinical trial markets and expanding its footprint in the US. IXICO reported revenue growth positive trends in 2024 and strong commercial momentum into 2025, with contract wins and pipeline expansion surpassing previous years. The company has intensified investments in AI-driven precision medicine innovation, clinical trial services, and expanded patient and trial data analytics capabilities. It continues to strengthen partnerships with global biopharma clients and expert imaging centers to maintain market leadership in neurological biomarker analysis and imaging solutions. IXICO’s core product and service portfolio includes imaging biomarker analytics; clinical trial imaging operations including site and project management; advanced AI algorithms for structural, molecular, and functional neuroimaging data analysis; digital data management; scientific and technical advisory services related to the use of biomarkers and imaging in neurology; and innovative AI-powered tools to monitor patient responses and support drug development decisions. The company supports all phases of clinical development from patient selection and trial monitoring to post-marketing surveillance. Its TrialTracker platform facilitates seamless coordination of complex clinical trial workflows on a secure digital platform, ensuring regulatory compliance and high-quality data delivery. IXICO serves the pharmaceutical, biotechnology, and research sectors, providing services globally with operations concentrated in the UK, Europe (including Switzerland, the Netherlands, Ireland), and extending its commercial reach in North America. It collaborates with leading pharma companies, innovative biotech firms, scientific consortia, and non-profit organizations focused on neurological disease research and treatment development. The company’s technology and scientific expertise are fundamental in advancing neuroscience drug discovery, de-risking clinical research, and accelerating the development and delivery of novel neurological therapies. In summary, IXICO plc is a leader in neuroscience imaging and biomarker analytics for neurological clinical trials, offering a comprehensive portfolio of AI-driven technology and expert services. The company’s recent strategic moves with leadership changes, capital raising, and market expansion reinforce its position in the growing neurodegenerative disease clinical research market. It continues to build on two decades of scientific innovation and operational excellence to support biopharma clients worldwide in developing new treatments for complex neurological disorders.
Percheron Therapeutics secures proposed WHO drug name for HMBD-002 cancer therapy
Walmart price target lowered by UBS as Q1 results miss elevated expectations
Bram Goorden discusses IXICO growth plans - ICYMI
Zscaler set to benefit from federal tailwinds boosting fourth quarter outlook: analysts
UK utility investors face prolonged uncertainty after worst sell-off since privatisation era
Cavendish sees IXICO forecasts as conservative after order book hits five-year high
Rigetti Computing tops Q1 earnings estimates as loss narrows
IXICO launches latest version of AI neuroimaging platform
IXICO boss says Medidata collab is poster child of partnership plans - ICYMI
Lindian secures US$11.6M facility with Malawian bank to support Kangankunde ramp-up
Dow Jones, Nasdaq close lower as US-Iran peace talks stall, UnitedHealth surges on earnings
Eli Lilly’s Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts
Rivian Automotive platform push unlikely to gain near-term traction, says UBS
Xcel Energy seen as undervalued as UBS lifts price target
Procter & Gamble cost pressures in focus for Q3 report
McDonald’s Q1 profit seen slightly below estimates as Jefferies trims sales outlook
Halliburton beats estimates as shares rise on early signs of North America recovery
Cavendish sees significant upside in IXICO as surging order book and £10m raise point to growth inflexion
Uranium American Resources completes JAG Minerals acquisition
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio